586 related articles for article (PubMed ID: 26743040)
1. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
[TBL] [Abstract][Full Text] [Related]
2. Sexual Rehabilitation After Nerve-Sparing Radical Prostatectomy: Free-of-Charge Phosphodiesterase Type 5 Inhibitor Administration Improves Compliance to Treatment.
Siena G; Mari A; Canale A; Mondaini N; Chindemi A; Greco I; Saleh O; Serni S; Nicita G; Minervini A; Carini M
J Sex Med; 2018 Feb; 15(2):120-123. PubMed ID: 29425663
[TBL] [Abstract][Full Text] [Related]
3. Is there a relationship between phosphodiesterase type 5 inhibitors and biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis.
He Q; Liao BH; Xiao KW; Zhou L; Feng SJ; Li H; Wang KJ
Int Urol Nephrol; 2018 Dec; 50(12):2113-2121. PubMed ID: 30232722
[TBL] [Abstract][Full Text] [Related]
4. Oncologic outcomes at 10 years following robotic radical prostatectomy.
Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
[TBL] [Abstract][Full Text] [Related]
5. Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?
Flores JM; Vertosick E; Jenkins LC; Cooper J; Benfante N; Sjoberg D; Vickers AJ; Eastham JA; Laudone VP; Scardino PT; Nelson CJ; Mulhall JP
J Urol; 2024 Mar; 211(3):400-406. PubMed ID: 38194487
[TBL] [Abstract][Full Text] [Related]
6. Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review.
Aoun F; Slaoui A; Walid AHO; Albisinni S; Assenmacher G; de Plaen E; Azzo JM; Peltier A; Roumeguère T
Prog Urol; 2018 Oct; 28(12):560-566. PubMed ID: 30201551
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported Side Effects 1 Year After Radical Prostatectomy or Radiotherapy for Prostate Cancer: A Register-based Nationwide Study.
Corsini C; Bergengren O; Carlsson S; Garmo H; Hjelm-Eriksson M; Fransson P; Kindblom J; Robinson D; Westerberg M; Stattin P; Carlsson SV
Eur Urol Oncol; 2024 Jun; 7(3):605-613. PubMed ID: 38233329
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.
Loeb S; Folkvaljon Y; Robinson D; Lissbrant IF; Egevad L; Stattin P
Eur Urol; 2016 Jun; 69(6):1135-41. PubMed ID: 26707871
[TBL] [Abstract][Full Text] [Related]
9. Utilization of pharmacotherapy for erectile dysfunction following treatment for prostate cancer.
Prasad MM; Prasad SM; Hevelone ND; Gu X; Weinberg AC; Lipsitz SR; Palapattu GS; Hu JC
J Sex Med; 2010 Mar; 7(3):1062-73. PubMed ID: 20059662
[TBL] [Abstract][Full Text] [Related]
10. A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy.
Gallina A; Bianchi M; Gandaglia G; Cucchiara V; Suardi N; Montorsi F; Briganti A
Eur Urol; 2015 Nov; 68(5):750-3. PubMed ID: 25700565
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence.
Jo JK; Kim K; Lee SE; Lee JK; Byun SS; Hong SK
Ann Surg Oncol; 2016 May; 23(5):1760-7. PubMed ID: 26717939
[TBL] [Abstract][Full Text] [Related]
12. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT).
Montorsi F; Brock G; Stolzenburg JU; Mulhall J; Moncada I; Patel HR; Chevallier D; Krajka K; Henneges C; Dickson R; Büttner H
Eur Urol; 2014 Mar; 65(3):587-96. PubMed ID: 24169081
[TBL] [Abstract][Full Text] [Related]
13. Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database.
Kimura M; Bañez LL; Gerber L; Qi J; Tsivian M; Freedland SJ; Satoh T; Polascik TJ; Baba S; Moul JW
J Sex Med; 2012 Apr; 9(4):1174-81. PubMed ID: 22188861
[TBL] [Abstract][Full Text] [Related]
14. Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO Trial.
Nyberg M; Hugosson J; Wiklund P; Sjoberg D; Wilderäng U; Carlsson SV; Carlsson S; Stranne J; Steineck G; Haglind E; Bjartell A;
Eur Urol Oncol; 2018 Oct; 1(5):353-360. PubMed ID: 31158073
[TBL] [Abstract][Full Text] [Related]
15. Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy: Results from the LAParoscopic Prostatectomy Robot Open Trial.
Sooriakumaran P; Pini G; Nyberg T; Derogar M; Carlsson S; Stranne J; Bjartell A; Hugosson J; Steineck G; Wiklund PN
Eur Urol; 2018 Apr; 73(4):618-627. PubMed ID: 28882327
[TBL] [Abstract][Full Text] [Related]
16. Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series.
Hubanks JM; Umbreit EC; Karnes RJ; Myers RP
Eur Urol; 2012 May; 61(5):878-84. PubMed ID: 22154730
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Phosphodiesterase 5 Inhibitor on Biochemical Recurrence Following Radical Prostatectomy in Patients with Prostate Cancer.
Chung JW; Kim JW; Ha YS; Choi SH; Lee JN; Kim BS; Kim HT; Yoo ES; Kwon TG; Kim TH
Urol J; 2019 Jun; 16(3):255-259. PubMed ID: 31204438
[TBL] [Abstract][Full Text] [Related]
18. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy.
Rieken M; Shariat SF; Kluth LA; Fajkovic H; Rink M; Karakiewicz PI; Seitz C; Briganti A; Rouprêt M; Loidl W; Trinh QD; Bachmann A; Pourmand G
Eur Urol; 2015 Dec; 68(6):949-56. PubMed ID: 26050111
[TBL] [Abstract][Full Text] [Related]
19. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
[TBL] [Abstract][Full Text] [Related]
20. Drug prescription for erectile dysfunction before and after diagnosis of localized prostate cancer.
Plym A; Folkvaljon Y; Garmo H; Holmberg L; Johansson E; Fransson P; Stattin P; Lambe M
J Sex Med; 2014 Aug; 11(8):2100-8. PubMed ID: 24862360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
